Nature Cancer

Article	Citations
Enhancing childhood cancer targetability	720
Shooting for multiplexed pathology with Orion	558
PARP11 interfer(on)es with CAR T cell efficacy	516
A macrophage-activated abscopal effect	420
An oncolytic circular RNA therapy	385
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	337
Considering molecular alterations as pan-cancer tissue-agnostic targets	329
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	314
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	295
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	289
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	255
Gut decisions in CAR T cell therapy	217
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	200
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	190
MALAT1 protects dormant tumor cells from immune elimination	186
Breaking frontiers with multidisciplinary cancer research	163
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	155
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	152
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	150
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	139
A low-coverage liquid biopsy for lung cancer	138
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	137
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	133
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	131
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study	127

The cGAS–STING pathway and cancer	125
Expanding the options for KRAS inhibition	124
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	123
Palmitate oxidation drives a pro-metastatic post-translational modification	123
A molecular glue halts RAS–MAPK signaling	118
The importance of being generous	117
Bone marrow progenitor-like cells against leukemia cure	116
Stress granules shape metabolic reprogramming and drug resistance	115
Shaping the microenvironment in peritoneal metastases	114
Impact of context-dependent autophagy states on tumor progression	109
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	109
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	109
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	109
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial	107
Advancing therapeutics in small-cell lung cancer	107
Determinants of resistance and response to melanoma therapy	107
Innate immunity drives epithelial cell plasticity during prostate tumor formation	105
Sarcoma ecotypes determine immunotherapy benefit	105
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	101
Antibody avidity meets multiple myeloma	101
Thriving in diverse ecosystems	100
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	98
Evolving landscape of nasopharyngeal carcinoma therapy	97
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	93
Inflammation meets translation in AML	92
Key insights from ESMO Congress 2025	92
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	89
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	89
A comeback for checkpoint inhibition in multiple myeloma	88
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	87
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	85
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	84
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial	84
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	83
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	83
Cycling back to folate metabolism in cancer	82
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	82
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	81
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	81
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	79
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	79
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	79
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	79
Radioligand cancer therapy comes to the fore	79
Immunotargeting of a recurrent AML-specific neoantigen	78
Multimodal data integration improves immunotherapy response prediction	78
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	78
Dual inhibition of EGFR and PI3K with a single drug	78
Building a translational cancer dependency map for The Cancer Genome Atlas	77

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	77
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	77
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	76
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	74
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	74
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	74
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	73
How AI agents will change cancer research and oncology	73
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	72
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	72
Selective targeting of malignant T cells	71
AKTing on XPO1 inhibition in AML	70
Highlights from the 2025 ASCO Annual Meeting	70
Bispecific chimeric T cell receptors tackle tumor heterogeneity	68
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	67
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	66
Regional delivery of hypoxia-responsive CAR T cells improves efficacy for solid tumors	64
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	63
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	63
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	63
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	63
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer	62
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	61
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	60
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	60
The tumor microenvironment’s role in the response to immune checkpoint blockade	60
Advances in antibody-based therapy in oncology	60
Anything to declare?	59
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	57
Epigenetic plasticity in PDAC	57
An unexpected career in cancer metabolism	56
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	56
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	56
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	56
Metabolic symbiosis in pancreatic cancer	56
In vivo macrophage engineering for renal cancer therapy	55
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	55
Neoadjuvant immunotherapy marks a new era in oncology	55
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	55
Myeloma evades T cell-engaging therapies	54
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	53
Ricolinostat is not a highly selective HDAC6 inhibitor	53
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors	53
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	53
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	52
p53 at the crossroads of tumor immunity	51
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	51
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	51
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	50
Clinical and translational attributes of immune-related adverse events	50
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	50
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	50
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	49
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	48
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	48
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	48
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p	47
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	47
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	45
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	45
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	45
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial	44
Understanding the biology of lung cancer brain metastases	44
CD8+ T cell killing of MHC class I–deficient tumors	44
Breaking the performance ceiling for neoantigen immunogenicity prediction	44
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	43
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	43
Masking T cell engagers mitigates on-target off-tumor activity	43
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	43
CAR T cell therapy: looking back and looking forward	42
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	42
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	42
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	41
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	41
Radiopharma pipeline builds ahead of key data	40
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	40
The meaning of impact	40
Near-infrared optogenetic engineering of bacteria for cancer therapy	40
Communicating with respect	40
Cellular neighborhoods in cancer	39

Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan	39
CD4+ CAR T cells — more than helpers	39
Leveraging the potential for deintensification in cancer care	39
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	38
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	38
Glucagon-like peptide-1 medicines and cancer	38
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results	37
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	37
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial	37
Leveraging translational insights toward precision medicine approaches for brain metastases	37
Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling	37
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	37
Artificial intelligence for prostate cancer diagnostics	37
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
Commensal metabolite boosts chemotherapy	36
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	36
A 180 degree turn en route to crafting a scientific career that never goes stale	36
Disparities, aging and childhood cancer	36
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	35
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	35
The aging lung reawakens dormant tumor cells	35
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	34
CDK10 inhibits innate sensing to constrain antitumor immunity	34
Harnessing foundation models for digital pathology without re-training	33
Fibrotic tumors tune metabolism for immune evasion	33
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	33
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	33
Targeting HIF-1 to treat AML	33
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	33
The landscape of T cell antigens for cancer immunotherapy	31
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	31
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	31
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis	31
CAR T cell therapy for multiple myeloma	30
Not a generative AI–generated Editorial	30
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer	30
The growing threat of cyberwarfare in cancer healthcare	30
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma	30
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	30
Bicarbonate transport as a vulnerability in pancreatic cancer	30
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells	29
The two sides of the γδ T cell coin	29
Remodeling cyclophilin A to target KRAS	29
Checking immunotoxicity risks of checkpoint blockade	29
Checkpoint blockade regulates T cell fate by supporting co-stimulation	29
Author Correction: Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy	29
T cells lead the charge against solid tumors	29
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation	28
Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC	28
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia	28
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	28
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	28
Exploiting HLA-DR mismatches for CAR therapy in acute myeloid leukemia	27
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma	27
The craft (and art) of scientific writing	27
Mini colons to study cancer ex vivo	27
The editors’ point of view	27
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma	26
Neutrophils determine immunotherapy success	26
Decoding TNBC architecture	26
SIGLEC9 tips the myeloid balance in glioblastoma	26
Understanding inequities in precision oncology diagnostics	26
Characterization of cis-regulatory elements and functional variants in colorectal cancer using epigenomics and CRISPRi screenings	26
European cancer research requires renewed urgency	26
Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer	26
Golgi pH buffers ferroptosis sensitivity	26
A roadmap of therapeutic strategies for patients with multiple myeloma	26
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo	26
Hallmarks of artificial intelligence contributions to precision oncology	25
Inferring early genetic progression in cancers with unobtainable premalignant disease	25
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy	25
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer	25
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer	25
Targeting TAK1 in microglia to treat CAR T cell neurotoxicity	24
Publisher Correction: TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	24
SOS1 inhibitor combinations overcome KRAS inhibitor resistance	24
Mind the GAP(43) for mitochondria transfer to glioblastomas	23
Glutamine analogs for pancreatic cancer therapy	23
Starfish infers signatures of complex genomic rearrangements across human cancers	23
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway	23
Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity	23
Charting the landscape of drug response and resistance with multiplexed ‘mosaic’ tumor models	22
Decoding tumor heterogeneity and plasticity	21
CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off	21
Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule	21
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis	20
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy	20
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study	20
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features	20
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	20
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	20
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features	20
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities	20
The 2022 generation	19